Dianthus Therapeutics (FRA:87E) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:87E Dianthus Therapeutics Inc FRA:87E
30 GF Score
Price €84.00
GF Value €2.48
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics SpecialCharges?

Special Charges only applies to banks.

FRA:87E
30GF Score
Dianthus Therapeutics Inc FRA:87E
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dianthus Therapeutics (FRA:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €84.00 is trading 3287.1% above its estimated GF Value™ of €2.48. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:87E:

  • SpecialCharges:
  • GF Value™: €2.48 vs. price of €84.00 (3287.1% above fair value)
  • GF Score™: 30/100 with 7 warning signs

No single metric tells the full story. See the FRA:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
30GF Score

Get the complete analysis for FRA:87E

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€84.00
Price
€2.48
GF Value